Logotype for Celldex Therapeutics Inc

Celldex Therapeutics (CLDX) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Celldex Therapeutics Inc

Q3 2026 earnings summary

5 Nov, 2026

Executive summary

  • Phase 3 CSU studies met primary and key secondary endpoints, supporting a planned 2027 BLA filing for barzolvolimab; treatment continues through Week 52.

  • Liquidity was $650.3M at September 30, with planned operations expected to be funded through 2028, subject to a potential milestone payment; 9M net loss widened as development and commercial-planning costs increased.

Financial highlights

  • Q3 R&D was $67.4M vs. $62.9M and G&A was $14.8M vs. $10.7M; 9M R&D was $208.0M vs. $169.7M and G&A was $39.4M vs. $31.9M.

  • Q3 operating expenses were $82.3M, up 12% YoY; 9M expenses rose 23% to $247.3M. Operating losses were $82.3M and $247.3M, respectively.

  • Net loss was $75.6M, or $0.96/share, in Q3 and $227.7M, or $3.06/share, for 9M; prior-year losses were $67.0M and $177.4M.

  • Q3 revenue was $0; 9M revenue was $37K vs. $1.424M, mainly reflecting lower Rockefeller University contract and services revenue.

Outlook and guidance

  • Planned FDA BLA submission for barzolvolimab in CSU in 2027; both Phase 3 CSU trials continue treatment through Week 52.

  • Phase 2 atopic dermatitis topline data expected in late 2026; ColdU and symptomatic dermographism Phase 3 studies are enrolling, with updates expected in 2027.

  • Cash used in operations is expected to increase over the next 12 months, primarily with barzolvolimab development; personnel, product development, facility and commercial-planning costs are also expected to rise.

  • Rockefeller services revenue may rise but fluctuate by quarter; additional barzolvolimab indications were planned for announcement by year end.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Celldex Therapeutics